EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Lack of clinical utility of serum macrophage migration inhibitory factor (MIF) for monitoring therapy response and estimating prognosis in advanced lung cancer

Alexander Rupp, Sophie Bahlmann, Nicolai Trimpop, Joachim von Pawel, Stefan Holdenrieder

Tumor Biology · 2024

DOI: 10.3233/tub-230006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tumor Biology, 2024. Verfasst von Alexander Rupp und 4 weiteren Autor:innen. Beteiligte Einrichtung: Munich Biomarker Research Center, Institute of Laboratory Medicine, German Heart Centre Munich, Munich, Germany. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Carcinoma, Non-Small-Cell Lung, Keratin-19, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lung cancer is a major burden to global health and is still among the most frequent and most lethal malignant diseases. Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine involved in a variety of processes including tumorigenesis, formation of a tumor microenvironment and metastasis. It is therefore a potential prognostic biomarker in malignant diseases. OBJECTIVE: In this study, we investigated the applicability of MIF in serum samples as a biomarker in lung cancer. METHODS: In a retrospective approach, we analyzed the sera of 79 patients with non-small-cell lung cancer (NSCLC) and 14 patients with small-cell lung cancer (SCLC) before the start of chemotherapy, as well as before the second and third chemotherapy cycle, respectively. Serum MIF levels were measured using a sandwich immunoassay with a sulfo-tag-labelled detection antibody, while pro-gastrin releasing peptide (proGRP) levels were determined with an enzyme-linked immunosorbent assay. RESULTS: No difference in serum MIF levels between responders and non-responders to chemotherapy was observed at all time points, while proGRP levels were significantly lower in responders before the second chemotherapy cycle ( p = 0.012). No differences in biomarker levels depending on the histopathological classification of NSCLC patients was found. Moreover, in ROC curve analyses MIF was not able to distinguish between responders and non-responders to therapy. proGRP could differentiate between responders and non-responders before the second chemotherapy cycle ( p = 0.015) with sensitivities of 43% at 90% and 95% specificity, respectively. Likewise, proGRP yielded significantly longer survival times of patients with low proGRP concentrations before the second chemotherapy cycle ( p = 0.015) in Kaplan-Meier analyses, yet MIF showed no significant differences in survival times at all time points. Comparison with the biomarkers CEA and CYFRA 21-1 in the same cohort showed that these established biomarkers clearly performed superior to MIF and proGRP. CONCLUSIONS: From the present results, there is no indication that serum MIF may serve as a biomarker in prognosis and monitoring of response to therapy in lung cancer. Limitations of this study include its retrospective design, the inclusion of a larger NSCLC and a smaller SCLC subgroup, the classical chemotherapeutic treatment, the use of a non-diagnostic immunoassay (RUO-test) for MIF measurement and the lack of a validation cohort. Strengths of the study are its highly standardized procedures concerning sample collection, preanalytic treatment, measurements and quality control of the laboratory assays.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmCarcinoma, Non-Small-Cell LungKeratin-19Lung NeoplasmsMacrophage Migration-Inhibitory FactorsSmall Cell Lung CarcinomaHumansBiomarkers, TumorIntramolecular OxidoreductasesPeptide FragmentsRecombinant ProteinsRetrospective StudiesTumor Microenvironment

Stichwörter der Autor:innen

BiomarkersMIFlung cancerproGRP

Substanzen

antigen CYFRA21.1Antigens, NeoplasmBiomarkers, TumorIntramolecular OxidoreductasesKeratin-19Macrophage Migration-Inhibitory FactorsMIF protein, humanPeptide FragmentsRecombinant Proteins

Autor:innen und Institutionen

  • Munich Biomarker Research Center, Institute of Laboratory Medicine, German Heart Centre Munich, Munich, Germany.
  • Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Asklepios Lungen-Fachkliniken München-Gauting, Gauting, Germany.

Zitieren

APA

Rupp, A., Bahlmann, S., Trimpop, N., von Pawel, J., & Holdenrieder, S. (2024). Lack of clinical utility of serum macrophage migration inhibitory factor (MIF) for monitoring therapy response and estimating prognosis in advanced lung cancer. Tumor Biology. https://doi.org/10.3233/tub-230006

Vancouver

Rupp A, Bahlmann S, Trimpop N, von Pawel J, Holdenrieder S. Lack of clinical utility of serum macrophage migration inhibitory factor (MIF) for monitoring therapy response and estimating prognosis in advanced lung cancer. Tumor Biology. 2024. doi:10.3233/tub-230006

BibTeX
@article{Rupp2024,
  author = {Rupp, Alexander and Bahlmann, Sophie and Trimpop, Nicolai and von Pawel, Joachim and Holdenrieder, Stefan},
  title = {Lack of clinical utility of serum macrophage migration inhibitory factor (MIF) for monitoring therapy response and estimating prognosis in advanced lung cancer},
  journal = {Tumor Biology},
  year = {2024},
  doi = {10.3233/tub-230006}
}
Kostenlos starten →